Form 4: Arvinas Director Everett Cunningham Reports Stock and Option Awards

Director Everett Cunningham reports the acquisition of restricted stock units and stock options in Arvinas, Inc.

Summary

• On May 29, 2024, Everett Cunningham, a director of Arvinas, Inc., reported the acquisition of 5,899 shares of common stock through restricted stock units (RSUs) and an option to purchase 9,070 shares of common stock.
• The RSUs were granted on May 29, 2024, and each RSU represents a contingent right to receive one share of Arvinas' common stock upon settlement for no consideration.
• The RSUs will vest in full on the earlier of May 29, 2025, or the first board of directors meeting after the next annual stockholder meeting.
• The stock option, also granted on May 29, 2024, has an exercise price of $33.90 and expires on May 28, 2034.
• These shares underlying the option will vest in full on the earlier of May 29, 2025, or the first board of directors meeting after the next annual stockholder meeting.
• Following these transactions, Cunningham directly owns 10,020 shares of Arvinas common stock and options to purchase 9,070 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reports standard equity grants to a director, which is generally viewed as a positive sign of aligning interests with shareholders. There are no explicit negative indicators.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of future value creation.

Industry Context

Equity grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders. This is a standard form filing related to those grants.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation to align director and shareholder interests.
• The vesting schedules are also typical, often tied to continued service or performance milestones.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to decisions that increase shareholder value.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates